Locally Advanced Gastric Carcinoma Clinical Trial
Official title:
A Multicenter, Randomized, Controlled Study of S-1 Combined With Oxaliplatin by Arterial Infusion Plus PD-1 Antibody Versus Conventional SOX Chemotherapy Plus PD-1 Antibody for Locally Advanced Gastric Cancer
SOX regimen, consisting of oral S-1 and intravenous oxaliplatin, is the preferred regimen for perioperative chemotherapy for gastric cancer. The goal of this clinical trial is to compare the efficacy and safety between S-1 combined with oxaliplatin by arterial infusion, as neoadjuvant chemotherapy, and conventional SOX regimen, in locally advanced gastric cancer. The main question it aims to answer is: whether arterially infused oxaliplatin plus S-1 has the potential to be a better neoadjuvant option for patients with locally advanced gastric cancer. Participants will be randomised, and receive: - 3 cycles of conventional SOX chemotherapy plus PD-1 antibody or arterial infused oxaliplatin plus S-1 and PD-1 antibody, as neoadjuvant chemotherapy; - Adequate gastric resection along with D2 lymph node dissection; - 3 cycles adjuvant chemotherapy using SOX regimen plus PD-1 antibody. - Administration of S-1 regularly till 1 year after surgery. Researchers will compare Major pathological response rate (MPR) ，pathologic complete response rate（pCR）,the 2-year overall survival (OS) rates, 2-year disease free survival (DFS), R0 resection rates, and adverse events, to see if the modified perioperative chemotherapy improve the prognosis of patients with locally advanced gastric cancer.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03223740 -
Preoperative Stomach Cancer Induction Chemotherapy and Radiation Therapy
|
Phase 3 | |
| Recruiting |
NCT06284746 -
Tirelizumab Combined With Chemotherapy in the Treatment of HER-2 Negative Locally Advanced Gastric Cancer
|
Phase 2 | |
| Recruiting |
NCT04891016 -
Toripalimab Plus FLOT in Locally Advanced Gastric Cancer
|
Phase 2 | |
| Recruiting |
NCT06396143 -
Research on Intelligent Screening and Decision-making for Neoadjuvant Therapy in Locally Advanced Gastric Cancer Based on Multi-omics Integration
|
||
| Completed |
NCT02048540 -
Neoadjuvant Bev Plus DOF vs DOF in LAGC and Its Association With Circulating Tumor Cell
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06364410 -
Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT04550494 -
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
|
Phase 2 |